Nautilus Bio Stock (NASDAQ:NAUT)
Previous Close
$1.81
52W Range
$1.78 - $3.46
50D Avg
$2.46
200D Avg
$2.57
Market Cap
$226.02M
Avg Vol (3M)
$110.27K
Beta
1.04
Div Yield
-
NAUT Company Profile
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DTIL | Precision BioSciences, Inc. |
| RVMD | Revolution Medicines, Inc. |
| BCAB | BioAtla, Inc. |
| IPSC | Century Therapeutics, Inc. |
| CRBU | Caribou Biosciences, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| HCWB | HCW Biologics Inc. |
| CCCC | C4 Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| CSBR | Champions Oncology, Inc. |
| RZLT | Rezolute, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| BEAM | Beam Therapeutics Inc. |
| MOLN | Molecular Partners AG |